NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Maha Katabi, PhD, CFA

Maha is a General Partner of Sofinnova Investments. She is an experienced investor in biopharma companies with over two decades in venture capital investing and public equities portfolio management. She focuses on development stage investments in therapeutics.